Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
Status:
Recruiting
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
This pilot study has been designed to investigate the safety of pembrolizumab treatment for
disease relapse following allogeneic stem cell transplant (alloSCT). Pembrolizumab will be
administered at a fixed dose of 200 mg IV every 3 weeks. Approximately 12-26 patients with
relapsed MDS, AML, or mature B cell (B-NHL, cHL) malignancies that have relapsed following
alloSCT will be enrolled on this trial. Pembrolizumab treatment will be administered for up
to 24 months, provided that neither disease progression, nor development of a dose-limiting
toxicity (DLT), has occurred. Adverse events will be monitored every three weeks throughout
the trial and graded in severity according to the guidelines outlined in the NCI Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0. This trial will be conducted in
accordance with Good Clinical Practices.